ClinicalTrials.gov
public full text
Public Domain
Endocannabinoid Control of Microglia Activation as a New Therapeutic Target in the Treatment of Schizophrenia
The main objective of this study is to compare microglia activation as measured with proton Magnetic Resonance Spectroscopy (1H-MRS) between recent-onset schizophrenia patients who are randomised to CBD and those randomised to placebo.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Evaluation of Microglial Activation in ALS With [18F]PBR06 (Peripheral Benzodiazepine Receptor-06) PET#893659
- Advanced analytical approaches for endocannabinoids and endocannabinoid-like substances: Applications in liver disease research.#458607
- The Brain Endocannabinoid System is Differentially Regulated in Male and Female Patients with First-Episode Psychosis.#157881
- Cannabis Potency Effects on Brain White Matter in Early Phase Psychosis#208422
- Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study#894433
Record · ID 902579
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive